Back to list

Biogen Lilac Study

University of North Carolina at Chapel Hill


To determine the safety and efficacy of a new biologic drug (BIIB059) in patients with Systemic or Cutaneous Lupus Erythematosus


Arthritis, Joints, Lupus, Skin


Drug or Biologic



18 - 75 years


Study Population

Males and females ages 18-75 years old, diagnosed with systemic or cutaneous lupus erythematosus (SLE/CLE), and have active skin involvement and/or joint swelling and tenderness.


Saira Sheikh
Clinical Assistant Professor
Medicine-UNCP A Rheumatology

For questions, contact:

Julie Norfleet

Recruitment Period End

December 31, 2018


Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 75 years

Participant qualification(s) Diagnosed with Systemic or Cutaneous Lupus Erythematosus and have active skin activity and/or joint swelling and tenderness of the hands.

Not eligible if: Patients who are pregnant or looking to become pregnant, and patients with active lupus nephritis

Number of Visits

    » 13 In person visit(s)

    1 Screening, 12 Clinic

    » 0 Remote visit(s)

Participation Period

40 weeks


$650 for completing the study, or $50 for each completed visit, as well as parking vouchers

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.